

February 1, 2024

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

F. Hoffmann-La Roche Announces Financial Results for Fiscal 2023

F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Thomas Schinecker] announced today its financial results for fiscal 2023 (January 1 – December 31, 2023).

Roche owns 59.89% of Chugai’s issued shares (61.13% of voting rights) as of the end of December 2023.

Its investor update and presentation materials can be found on its website (<https://www.roche.com>).

Chugai’s performance for the period of January 1 to December 31, 2023 is included in the announced Roche Group’s results.

[Investor Updates](#)

[Reporting](#)

###